← All trials
NCT04897516
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 28, 2023
- First posted
- May 21, 2021
- Last posted
- Sep 17, 2021
- Enrollment
- 362
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Laboratorio Elea S.A.C.I.F. y A.Lead sponsor
- Drugs for Neglected Diseases InitiativeCollaborator
- Drugs for Neglected Diseases InitiativeStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.